Isracann Biosciences Inc.

ISCNFOTCHealthcare● Active

$0.00

+$0.00(+0.00%)

Market Cap$1760

P/E Ratio—

52W High$0.0001

52W Low$0.00001

Avg Volume43K

Open$0.00

Beta0.19

Free Cash Flow Financials Revenue

Isracann Biosciences Inc. (ISCNF) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

ISCNF · free cash flow · updated Jun 9, 2026

Core FCF metrics

ISCNF · FCF · TTM · margin & CAGR

Free cash flow was −$1.8M for FY2022 (fiscal year ending 2022-05-31), up 58.7% year-over-year

FY2022 Free Cash Flow−$1.8M▲ +58.7% YoY

Trailing 12M (TTM)−$1.5Mtrailing 4 quarters sum

FCF Margin——

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

ISCNF · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2022Latest−$1.8M(0M)−$1.8M▲ +58.7%—

FY2021−$4.2M(0M)−$4.2M▲ +61.1%—

FY2020−$10.4M(1M)−$10.9M▼ 246.7%—

FY2019−$2.9M(0M)−$3.1M▲ +64.7%—

FY2018−$2.9M(6M)−$8.9M▼ 1474.8%-760.2%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

ISCNF · P/FCF · FCF yield · FCF per share

Isracann Biosciences Inc. (ISCNF) reported negative free cash flow of −$0.00B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2022 · 2022-05-31

Cash flow statement summary

ISCNF · cash flow statement · operating / investing / financing

For FY2022, Isracann Biosciences Inc. generated −$1.8M in operating cash flow and spent 0M in capital expenditures, yielding −$1.8M in free cash flow.

Operating Activities

−$1.8M

Cash from core business operations

2022-05-31

Investing Activities

−$0.1M

CapEx, acquisitions & investments

2022-05-31

Financing Activities

+$0.1M

Buybacks, dividends & debt

2022-05-31

FCF FormulaOperating CF (−$1.8M) − |CapEx| (0M) = FCF (−$1.8M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

ISCNF vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Isracann Biosciences Inc.YOU

ISCNF

−$1.8M+58.7%—

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Isracann Biosciences Inc. (ISCNF) reported free cash flow of −$1.8M for FY2022 (fiscal year ending 2022-05-31), up 58.7% year-over-year.

Isracann Biosciences Inc. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 12 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

ISCNF free cash flow · 8 questions

Isracann Biosciences Inc. free cash flow was −$1.8M for FY2022, up 58.7% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$1.5M.

ISCNF free cash flowISCNF FCFISCNF FCF 2022ISCNF free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Isracann Biosciences Inc. · Isracann Biosciences Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026